2024 McDonald标准在非特异性症状或偶然影像发现个体中的多中心应用
该多中心横断面事后分析基于CVS in MS研究,评估非特异性症状或偶然影像提示脱髓鞘的成人中2024 McDonald标准的诊断阳性率。生物标志物尤其是中央静脉征贡献了相当比例的诊断阳性率。
要点
- 非特异性症状或偶然影像人群中约19%基线满足2024 McDonald标准。
- 偶然影像组诊断阳性率(32%)高于非特异性症状组(17%)。
- 中央静脉征等生物标志物对诊断分类贡献显著。
核心结论
- 应用2024 McDonald标准可使近五分之一无典型表现的个体在基线即满足MS诊断标准。
研究设计与样本
- 多中心观察性队列(CVS in MS研究)的横断面事后分析。
- 纳入18-65岁因疑似MS转诊的成人,由专家小组裁定,聚焦非特异性症状或偶然影像提示脱髓鞘者。
- 共420例入组,191例(45%)纳入分析:非特异性症状166例,偶然影像25例。
- 基线满足2024 McDonald标准为主要结局,采用Select-6 CVS和CSF OCBs判定。
主要发现
- 非特异性症状组28例(17%)满足标准,偶然影像组8例(32%)满足标准。
- 51例满足2017 DIS者中,22例(43%)Select-6阳性,17例(33%)OCB阳性,4例(8%)满足2017 DIT。
关键数值与推荐
- 2024 McDonald标准允许在非特异性症状或偶然影像提示脱髓鞘且生物标志物支持时诊断MS。
- DIS和DIT采用2017 MRI标准评估。
- Select-6 CVS评估所有参与者可得,OCB数据仅部分参与者基于既往临床评估可得。
临床怎么用
- 对非特异性症状或偶然影像提示脱髓鞘者,可结合2024 McDonald标准及CVS、OCB等生物标志物评估MS诊断。
局限性
- CSF数据仅部分参与者可得。
- 缺乏纵向随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The 2024 McDonald criteria allow diagnosis of multiple sclerosis (MS) in individuals presenting with symptoms not specific for MS or incidental imaging findings suggestive of demyelination when supported by biomarker evidence, reflecting a shift toward diagnostic definitions increasingly grounded in biological mechanisms of disease. The diagnostic yield of these criteria in such populations has not been evaluated in multicenter cohorts. We aimed to determine the proportion of individuals with nonspecific or incidental imaging presentations who meet the 2024 McDonald criteria and describe the contribution of central vein sign and CSF oligoclonal bands (OCBs) to diagnostic classification. METHODS: This cross-sectional post hoc analysis used data from the Central Vein Sign in Multiple Sclerosis study, a multicenter observational cohort. Adults aged 18-65 years referred for diagnostic evaluation of possible MS were adjudicated by an expert panel. This analysis focused on participants with symptoms not specific for MS or incidental imaging findings suggestive of demyelination. Dissemination in space (DIS) and dissemination in time (DIT) were assessed using 2017 MRI criteria. Fulfillment of the 2024 McDonald criteria at baseline-the primary outcome-was determined using the Select-6 CVS and CSF OCBs. Select-6 assessment was available for all participants, whereas OCB data were available for a subset based on prior clinical evaluation. RESULTS: Of 420 participants enrolled, 191 (45%) presented with either nonspecific symptoms (n = 166) or incidental imaging findings (n = 25). The mean age was 42 years, and 78% were female. Thirty-six (19%) met the 2024 McDonald criteria at baseline, including 28 (17%) in the nonspecific symptom cohort and 8 (32%) in the incidental imaging cohort. Among 51 participants meeting 2017 DIS, 22 (43%) were Select-6 positive, 17 (33%) had positive OCBs, and 4 (8%) met 2017 DIT. Nonspecific sensory symptoms, visual disturbances, and subacute cognitive decline were most associated with a diagnosis of MS. DISCUSSION: Application of the 2024 McDonald criteria identified nearly one-fifth of individuals without typical presentations as meeting diagnostic criteria for MS at baseline. Biomarker incorporation-particularly the CVS-accounted for a substantial proportion of diagnostic yield. Interpretation is limited by availability of CSF data and absence of longitudinal follow-up.
引用
- Scharf A, Cohen JA, Marrie RA, et al. Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study. Neurology. 2026. PMID: 42284534. doi:10.1212/WNL.0000000000218183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。